• Email
  • Help

Questions & Answers

On 15 February 2018,the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion[1], recommending the granting of a marketing authorisation for the veterinary medicinal product Clevor 30 mg/ml eye drops, solution in single-dose container, intended for the induction of vomiting in dogs. The applicant for this veterinary medicinal product is Orion Corporation.

Clevor is an emetic medicinal product containing ropinirole (as the hydrochloride) (ATCvet code QN04BC04) as the active substance. Ropinirole is a dopamine agonist which induces vomiting by activating receptors in the chemoreceptor trigger zone in the brain.

The benefits of Clevor are its efficacy in the induction of vomiting. The product also provides a new route of administration for an emetic medicine for dogs, and would increase the range of available treatment options. The most common side effects are transient mild or moderate hyperaemia of the eye, ocular discharge, protrusion of the third eyelid and blepharospasm, transient mild lethargy and increased heart rate.

The appropriate CVMP guidelines on data requirements for veterinary medicinal products intended for minor use or minor species/limited markets have been applied in the assessment of the application.

Detailed conditions for the use of this product will be described in the summary of product characteristics (SPC) which will be published in the European public assessment report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Clevor and therefore recommends the granting of the marketing authorisation.

[1] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Name Language First published Last updated
CVMP summary of positive opinion for Clevor (English only) 2018-02-16  

Key facts

Product details for Clevor
INN or common name


Active substance

ropinirole hydrochloride

Date opinion adopted15/02/2018
Company name

Orion Corporation

Application typeInitial authorisation